Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof

• US 20060188921A1
• Filed: 04/24/2006
• Published: 08/24/2006
• Est. Priority Date: 04/03/2001
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Legault, Holly, O' Toole, Margot
• Application Number:
  US11/409,906
• Publication Number:
  US 20060188921A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described.

Claims

1. A method of diagnosing a subject with systemic lupus erythematosus, the method comprising the step of comparing:

a) a level of expression of a marker in a sample from the subject, wherein the marker is a transcribed polynucleotide or a portion thereof, wherein the marker hybridizes under stringent conditions to mouse retinoic acid-responsive protein mRNA, and

b) a normal level of expression of the marker in a control sample,

wherein a difference between the level of expression of the marker in the sample from the subject and the normal level by a factor of at least about 2 is an indication that the subject is afflicted with systemic lupus erythematosus.

2. The method of claim 1, wherein the sample is collected from kidney tissue.

3. The method of claim 1, wherein the control sample is from a non-diseased subject.

4. The method of claim 1, wherein the control sample is from non-involved tissue of the subject.

5. The method of claim 1, wherein the transcribed polynucleotide is an mRNA.

6. The method of claim 1, wherein the transcribed polynucleotide is a cDNA.